Item 2.02 Results of Operations and Financial Condition.
On February 2, 2023, Bristol-Myers Squibb Company (the "Company") issued a press
release (the "Earnings Press Release") announcing its financial results for the
fourth quarter of 2022 and full year of 2022. A copy of the Earnings Press
Release is furnished pursuant to this Item 2.02 as Exhibit 99.1 to this Current
Report on Form 8-K and incorporated by reference herein in its entirety. Also
furnished pursuant to this Item 2.02 as Exhibit 99.2 to this Current Report on
Form 8-K and incorporated by reference herein in its entirety is certain
supplemental information (the "Supplemental Information") posted on the
Company's website at www.bms.com.
Item 7.01 Regulation FD Disclosure.
On February 2, 2023, the Company posted on its website at www.bms.com a
presentation (the "Bristol Myers Presentation") on certain financial and
operating initiatives available for viewing during the Company's conference call
and webcast announcing its financial results for the fourth quarter of 2022 and
full year of 2022 at 9:00 a.m. Eastern time on February 2, 2023. A copy of the
Bristol Myers Presentation is furnished pursuant to this Item 7.01 as Exhibit
99.3 to this Current Report on Form 8-K and incorporated by reference herein in
its entirety. The Earnings Press Release and the Bristol Myers Presentation
includes references to non-GAAP financial information. Reconciliations between
the non-GAAP financial measures and the comparable GAAP financial measures are
available in the Supplemental Information, which is included as Exhibit 99.2
hereto, and the reasons for the presentation of such non-GAAP financial measures
are available in the Earnings Press Release, which is included as Exhibit 99.1
hereto. The Bristol Myers Presentation should be read in conjunction with the
Supplemental Information and the Earnings Press Release. The Company reserves
the right to discontinue availability of the Bristol Myers Presentation from its
website at any time.
Pursuant to General Instruction B.2. to Form 8-K, the information set forth in
this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1, 99.2
and 99.3, shall not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise
subject to the liabilities thereof, nor shall it be incorporated by reference
into future filings by the Company under the Exchange Act or under the
Securities Act of 1933, as amended, except to the extent specifically provided
in any such filing. Additionally, the submission of the information set forth in
this Item 7.01 is not deemed an admission as to the materiality of any
information in this Current Report on Form 8-K that is required to be disclosed
solely by Regulation FD.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The following exhibits are furnished as part of this Current Report on Form 8-K:
Exhibit
No. Description
99.1 Press release of Bristol-Myers Squibb Company dated February 2, 2023.
99.2 Certain supplemental information posted on Bristol-Myers Squibb Company's website
at www.bms.com not included in the press release.
99.3 Presentation Materials of Bristol-Myers Squibb Company dated February 2, 2023.
The cover page from this Current Report on Form 8-K formatted in Inline XBRL
104 (included as Exhibit 101).
© Edgar Online, source Glimpses